Endogenous salivary inhibitors of Human Immunodeficiency Virus

被引:45
|
作者
Shugars, DC [1 ]
Alexander, AL
Fu, K
Freel, SA
机构
[1] Univ N Carolina, Sch Dent, Dept Dent Ecol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dent Res Ctr, Chapel Hill, NC 27599 USA
关键词
human immunodeficiency virus; AIDS; inhibitors; secretory leucocyte protease inhibitor; saliva;
D O I
10.1016/S0003-9969(99)00003-5
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
The human immunodeficiency virus type 1 (HIV-1) is rarely transmitted through salivary secretions, due in part to the presence of endogenous inhibitors. Here, the protective characteristics of the intraoral environment are summarized and inhibitory factors that reduce HIV-1 infectivity in vitro described, focusing on secretory leucocyte protease inhibitor (SLPI), a 12-kDa mucosal protein that blocks HIV infection in several cell-culture systems. SLPI appears to interact with a cellular surface molecule to limit viral entry into target cells. To determine whether the inhibitor has a similar role in vivo, the contribution of salivary SLPI to anti-HIV-1 activity was assessed. Whole unstimulated filtered salivas from infected and uninfected donors contained similar concentrations of the inhibitor, Depletion from SLPI filtered saliva produced a corresponding loss of inhibitory activity. In general, filtered whole salivas obtained from 10 donors had antiviral activities that correlated positively with SLPI concentrations. However, some samples having SLPI well below the concentration required for inhibitory activity in vitro exhibited modest inhibition, suggesting the presence of other anti-HIV-1 components in oral fluids. Thus, SLPI is a major but not sole inhibitor of this virus in saliva. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:445 / 453
页数:9
相关论文
共 50 条
  • [41] SULFONIC-ACID POLYMERS AS A NEW CLASS OF HUMAN-IMMUNODEFICIENCY-VIRUS INHIBITORS
    MOHAN, P
    SCHOLS, D
    BABA, M
    DECLERCQ, E
    ANTIVIRAL RESEARCH, 1992, 18 (02) : 139 - 150
  • [42] Human immunodeficiency virus and menopause
    Kanapathipillai, Rupa
    Hickey, Martha
    Giles, Michelle
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (09): : 983 - 990
  • [43] Human immunodeficiency virus and the brain
    Glass, JD
    Johnson, RT
    ANNUAL REVIEW OF NEUROSCIENCE, 1996, 19 : 1 - 26
  • [44] Human immunodeficiency virus and anaesthesia
    Khalpey, M.
    SOUTH AFRICAN FAMILY PRACTICE, 2012, 54 (03) : S7 - S10
  • [45] MICROBIOLOGY OF HUMAN-IMMUNODEFICIENCY-VIRUS ANORECTAL DISEASE
    GOLDBERG, GS
    ORKIN, BA
    SMITH, LE
    DISEASES OF THE COLON & RECTUM, 1994, 37 (05) : 439 - 443
  • [46] Critical care of immunocompromised patients: Human immunodeficiency virus
    Rosen, Mark J.
    Narasimhan, Mangala
    CRITICAL CARE MEDICINE, 2006, 34 (09) : S245 - S250
  • [47] Thirty years of the human immunodeficiency virus epidemic and beyond
    Younai, Fariba S.
    INTERNATIONAL JOURNAL OF ORAL SCIENCE, 2013, 5 (04) : 191 - 199
  • [48] Human Immunodeficiency Virus in an Aging Population, a Complication of Success
    Kirk, Jason B.
    Goetz, Matthew Bidwell
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2009, 57 (11) : 2129 - 2138
  • [49] Ocular syphilis in patients with Human Immunodeficiency Virus infection
    Mitchell, John P.
    Huang, Lynn L.
    Rosberger, Daniel F.
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2015, 107 (02) : 130 - 132
  • [50] Mucocutaneous manifestations in children with human immunodeficiency virus infection
    Mendiratta, Vibhu
    Mittal, Saurabh
    Jain, Arpita
    Chander, Ram
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2010, 76 (05) : 458 - 466